Clinical Trials · NCT02083185

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

Name: A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Gonadorelin

Phase: Phase 2
Recruitment status: Completed
Sponsor: Millennium Pharmaceuticals, Inc.
Enrollment: 136
Start date: Mar 2014
Locations: 23 sites, United States, Canada
Primary endpoint: Percentage of Participants With Effective Castration Rate Over 24 Weeks

View Gonadorelin compound reference